Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 19;12:5045. doi: 10.1038/s41467-021-25188-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Mean node size (cm) of abnormal nodes post-neoadjuvant chemotherapy as compared to pre-therapy in ICON patients. Data are shown as mean node size in cm ±SD. Two-sided P value is from linear mixed-effects model. N₁ = 13 nodes analyzed in nine patients. N₂ = 13 nodes analyzed in nine patients. b Mean node SUV_max of abnormal nodes post-neoadjuvant chemotherapy as compared to pre-therapy in ICON patients. Data are shown as mean node SUV_max ±SD. Two-sided P value is from linear mixed-effects model. N₁ = 6 nodes analyzed in three patients. N₂ = 6 nodes analyzed in three patients. c, d Mean node size (c) and SUV_max (d) of abnormal nodes post-neoadjuvant ICIs as compared to pre-therapy in NEOSTAR patients with NIF. Data are shown as mean node size in cm ±SD in panel (c) and mean SUV_max ±SD in panel (d). N₁ = 38 nodes analyzed in seven patients. N₂ = 38 nodes analyzed in seven patients. Two-sided P value is from linear mixed-effects model. The red circles and squares depict the node size and SUV_max collected from pre-therapy and post-therapy, respectively, in the NIF group. e, f Mean node size (e) and SUV_max (f) of abnormal nodes post-neoadjuvant ICIs as compared to pre-therapy in NEOSTAR patients with No-NIF. Data are shown as mean node size in cm ±SD in panel (e) and mean SUV_max ±SD in panel (f). N₁ = 40 nodes analyzed in 17 patients (e); 34 nodes analyzed in 15 patients (f) with available scans/images. N₂ = 40 nodes analyzed in 17 patients (e); 34 nodes analyzed in 15 patients (f) with available scans/images. Two-sided P value is from linear mixed-effects model. The blue circles and squares depict the node size and SUV_max collected from pre-therapy and post-therapy, respectively, in the No-NIF group. g Difference in mean size of abnormal nodes between post- and pre-therapy in NEOSTAR patients with NIF as compared with those with No-NIF. Data are shown as change in mean node size in cm ±SE. N₁ = 38 nodes analyzed in seven patients. N₂ = 40 nodes analyzed in 17 patients. Two-sided P value is from linear mixed-effects model. The red circles depict the change of node size in NIF group, and the blue squares depict the change of node size in No-NIF group. h Difference in mean SUV_max of abnormal nodes between post- and pre-therapy in NEOSTAR patients with NIF as compared with those with No-NIF. Data are shown as change in mean node SUV_max ±SE. N₁ = 38 nodes analyzed in seven patients. N₂ = 34 nodes analyzed in 15 patients. Two-sided P value is from linear mixed-effects model. The red circles depict the change of node SUV_max in NIF group, and the blue squares depict the change of node SUV_max in No-NIF group. ICON, ImmunogenomiC prOfiling in NSCLC; NIF, nodal immune flare; ICIs, immune checkpoint inhibitors; SUV, standardized uptake value; SD, standard deviation; SE, standard error. Source data are provided as a Source Data file.